This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
New treatment approved by PBAC for pouchitis
Chronic pouchitis looks set to be added to the list of PBS indications for vedolizumab, following a positive recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC).
Branded Entyvio, the agent was put forward for listing under the new indication by its importer, Takeda, under the Section 100 (Highly Specialised Drugs Program) at the PBAC’s meeting in July.
CCA looks forward to government advice on when this will be listed on the PBS.